Bristol-Myers Squibb is expected to report its second-quarter earnings later this month, and Wall Street is calling for a double-digit decrease in profit.
2 Cash-Producing Stocks Worth Investigating and 1 Facing Headwinds
3 Unpopular Stocks with Questionable Fundamentals
Tempus AI's stock has hit a rough patch, but fundamentals remain solid. What does it mean for investors?
1 S&P 500 Stock with Solid Fundamentals and 2 We Avoid
Bristol Myers Squibb (NYSE: BMY) will announce results for the second quarter of 2026 on Thursday, July 30, 2026. Company executives will review financial results with the investment community...
Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-three cents ($0.63) per share on the $0.10 par value common stock of the...
Multiple myeloma is a complex and incurable blood cancer, characterized by a relentless cycle of relapse and progressively shorter remissions ...
3 Value Stocks We Think Twice About
Bristol-Myers Squibb has underperformed the Dow recently, yet analysts remain moderately optimistic about the stock’s prospects.